Ubs Group Ag Aeglea Bio Therapeutics, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
BUY
$0.11 - $0.46 $889 - $3,718
8,084 Added 115485.71%
8,091 $3,000
Q1 2023

May 12, 2023
SELL
$0.29 - $0.61 $0 - $0
-1 Reduced 12.5%
7 $0
Q4 2022

Feb 08, 2023
BUY
$0.35 - $1.54 $2 - $12
8 New
8 $0
Q2 2022

Aug 10, 2022
BUY
$0.5 - $2.66 $5,765 - $30,669
11,530 Added 17.66%
76,806 $39,000
Q1 2022

May 16, 2022
SELL
$1.87 - $4.77 $133,443 - $340,387
-71,360 Reduced 52.23%
65,276 $150,000
Q4 2021

Feb 14, 2022
BUY
$3.5 - $8.42 $288,456 - $693,942
82,416 Added 152.0%
136,636 $649,000
Q3 2021

Nov 15, 2021
BUY
$6.03 - $7.95 $12,922 - $17,036
2,143 Added 4.12%
54,220 $431,000
Q2 2021

Aug 13, 2021
BUY
$6.32 - $8.38 $13,297 - $17,631
2,104 Added 4.21%
52,077 $362,000
Q1 2021

May 12, 2021
BUY
$6.76 - $8.57 $31,183 - $39,533
4,613 Added 10.17%
49,973 $396,000
Q4 2020

Feb 11, 2021
BUY
$7.02 - $9.83 $56,686 - $79,377
8,075 Added 21.66%
45,360 $357,000
Q3 2020

Nov 12, 2020
SELL
$6.51 - $9.33 $40,908 - $58,629
-6,284 Reduced 14.42%
37,285 $264,000
Q2 2020

Jul 31, 2020
SELL
$4.01 - $11.04 $1,872 - $5,155
-467 Reduced 1.06%
43,569 $403,000
Q1 2020

May 01, 2020
SELL
$3.51 - $8.48 $38,494 - $93,000
-10,967 Reduced 19.94%
44,036 $205,000
Q4 2019

Feb 14, 2020
SELL
$7.23 - $8.55 $26,505 - $31,344
-3,666 Reduced 6.25%
55,003 $420,000
Q3 2019

Nov 14, 2019
BUY
$6.42 - $9.0 $102,135 - $143,181
15,909 Added 37.21%
58,669 $451,000
Q2 2019

Aug 14, 2019
BUY
$6.1 - $8.78 $4,044 - $5,821
663 Added 1.57%
42,760 $293,000
Q1 2019

May 14, 2019
SELL
$7.6 - $9.4 $4,020 - $4,972
-529 Reduced 1.24%
42,097 $339,000
Q4 2018

Feb 14, 2019
SELL
$6.51 - $10.19 $68,641 - $107,443
-10,544 Reduced 19.83%
42,626 $319,000
Q3 2018

Nov 14, 2018
SELL
$8.24 - $11.0 $171,762 - $229,295
-20,845 Reduced 28.16%
53,170 $509,000
Q2 2018

Aug 14, 2018
BUY
$7.87 - $10.89 $389,171 - $538,510
49,450 Added 201.3%
74,015 $784,000
Q1 2018

May 15, 2018
BUY
$5.07 - $10.9 $117,821 - $253,305
23,239 Added 1752.56%
24,565 $244,000
Q4 2017

Feb 14, 2018
SELL
$4.0 - $5.98 $2,512 - $3,755
-628 Reduced 32.14%
1,326 $7,000
Q3 2017

Nov 14, 2017
SELL
$2.91 - $4.93 $1,903 - $3,224
-654 Reduced 25.08%
1,954 $10,000
Q2 2017

Aug 14, 2017
BUY
N/A
1,621 Added 164.24%
2,608 $10,000
Q1 2017

Nov 14, 2017
BUY
N/A
987
987 $7,000

Others Institutions Holding AGLE

# of Institutions
1
Shares Held
241K
Call Options Held
0
Put Options Held
0
View Full List

About Aeglea BioTherapeutics, Inc.

AGLE Quotes by TradingView
  • Ticker AGLE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,172,500
  • Market Cap $1.69B
  • Description
  • Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...
More about AGLE
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email